First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromat... ( BELLEVUE Wash. Aug. 12 /-...)

First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromatosis Study

Date:8/12/2009

BELLEVUE, Wash., Aug. 12 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated drug Aptocine(TM) (talaporfin sodium) in neurofibromatosis type 1 (NF-1). Investigators at the Neurofibromatosis/Neuro-Oncology Clinic of Children's Hospital of Philadelphia (CHOP) treated a pediatric patient with NF-1 and plexiform neurofibromas (PN) using Aptocine, which is also in late-stage development for solid tumors. The Neurofibromatosis/Neuro-Oncology Clinic is a program providing care and treatment for children with brain tumors and children with NF-1 and severe and/or life-threatening tumors. Michael Fisher, M.D., at CHOP's Division of Oncology, is the principal investigator of the study.

"A clinical trial in neurofibromatosis is an exciting step forward in the development of Aptocine for patients with a significant unmet medical need outside our primary cancer focus. I am proud and delighted that LSO is now associated with developing a treatment of this condition in children and adults," said LSO's President and CEO, Llew Keltner, M.D., Ph.D.

The goal of the study is to enroll 18-24 patients between 3 and 21 years of age with debilitating, severely disfiguring, life-threatening, or progressive PN tumors that are not surgically resectable, and for which no other standard medical management exists. Complete information on the study is available at ClinicalTrials.gov with the identifier: NCT00716469.

NF-1 is a common, autosomal dominant genetic disorder with an incidence of 1 in 2500 people (> 80,000 in the US); symptoms of NF-1 usually appear at birth and/or during infancy. PN represents one of the most significant complications of NF-1. PN tumors form along peripheral nerves and can become very large. Although PN tumors are not a major cause of mortality in pati
'/>"/>

SOURCE Light Sciences Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. William Stanfield, MD, Is First Cleveland-area Orthopedic Surgeon to Perform OtisKnee Custom Fit Knee Replacement
3. Imagenetix, Inc. Reports First Quarter 2010 Results
4. Synthetech Reports First Quarter Fiscal 2010 Results
5. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
6. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
7. Hoya Announces First Quarter Financial Results for FY2010
8. Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
10. First genetically engineered malaria vaccine to enter human trials
11. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009

Post Your Comments:

(Date:12/15/2009)... -- Epeius Biotechnologies Corporation, an emerging leader in ... validation of the cutting-edge science behind its lead ... the world rediscovered the Cyclin G1 gene ... pathogenesis and disease progression, and thus a prime ... NIH National Cancer Institute investigating the role of ...

(Date:12/15/2009)... WALTHAM, Mass., Dec. 15 Repligen Corporation ... Company has received $731,000 in research funding to ... Friedreich,s ataxia from the Muscular Dystrophy Association (MDA). ... preclinical GLP toxicology testing and GMP manufacture of ... Support from the MDA not only provides important ...

(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...

(Date:12/15/2009)... WILMINGTON, Del. and CHARLOTTESVILLE, Va., Dec. 15 ... ) and the University of Virginia (UVa) ... entered into a strategic research collaboration to ... coronary artery disease (CAD) with a secondary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) ,, The ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease

... DCGN ) today announced that it will report its third ... on Monday, November,5, after the close of the market in ... conference call to discuss these results and recent,operating highlights on ... The webcast can be accessed through the Investors page of ...

... Rises 6%; Clinical Diagnostics Grows 9.4%; On Target to ... Achieve Full ... BEC ), a leading developer, manufacturer and marketer of,products that ... September 30, 2007 results. Total,revenue of $669 million was up 6.0% ...

... Ventaira Pharmaceuticals,announced today that Battelle, a science ... assist Ventaira in closing its,operations. Financial terms of ... be working with Battelle to transition our assets. ... explore employment,opportunities for our employees," said Leslie Williams, ...

deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2007 Financial Results Beckman Coulter Announces Third Quarter 2007 Results Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle

(Date:12/16/2009)... Signal Hill, CA Tom Bowman, an expert ... of Bowman Global Change, has developed a series of ... Panel on Climate Change (IPCC) report for public audiences. ... scientific information they need to make informed decisions about ... new format as a means to clearly and accurately ...

(Date:12/16/2009)... YORK, Dec. 1 iQor, a global provider ... the 2009 InfoWorld 100 Awards Top 100 ... TeQ21. This was the first submission for iQor. ,, ... list of companies," said Vikas Kapoor, president and CEO ... do business, allowing us to work faster, smarter and ...

(Date:12/16/2009)... REDWOOD CITY, Calif., Dec. 2 ... and authentication solutions, today announced an agreement ... of its DigitalPersona biometric fingerprint technology on ... U.are.U® 4500HD offering allows point-of-sale applications to ... that specific transactions can be linked to ...

Breaking Biology News(10 mins):Bowman creates graphic translation of climate change data 2 iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2 DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2 The Tile Doctor Launches Inaugural Product Line 14086 1 The Tile Doctor Launches Inaugural Product Line 14086 2 The Tile Doctor Launches Inaugural Product Line 14086 3 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 1 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 2 Video 3A Members of Congress Receive Legislative Awards From National Amputee Organizations 57326 3 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 1 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 2 Premion First in Australia to Treat Cancer Patients with RapidArc 28R 29 Radiotherapy Technology from Varian Medical Systems 57324 3

[0] Bowman creates graphic translation of climate change data [0] iQor Named to InfoWorld 100 List of Top IT Projects of 2009 [0] DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems

... person,s body mass consisting of skeletal muscle, chronic inflammation ... the limbs can result in significant physical impairment. ... health professor Kimberly Huey, past research has demonstrated that ... with reduced expression of certain pro-inflammatory cytokines, in vitro, ...

... be published by Springer as of January 2009. The ... previously published by Wiley-Blackwell, is respected internationally for the ... broad range of subject areas relevant to fisheries science. ... Fisheries Science includes original and review articles ...

... 2008. The first 5-year forest inventory report for California,s ... public: California,s Forest Resources, 2001-2005: Five-Year Forest Inventory and ... report:, , Forests cover about a third of ... managed. , Houses built in the wildland-urban interface account ...

Other Biology News:Vitamin E shows possible promise in easing chronic inflammation 2 Vitamin E shows possible promise in easing chronic inflammation 3 Forest inventories in California include more than trees 2 Forest inventories in California include more than trees 3

Vitamin E shows possible promise in easing chronic inflammation Springer to publish Fisheries Science as of 2009 Forest inventories in California include more than trees

... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...

Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...

Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...

... raised against a partial recombinant NFKBIB. ... 145 a.a) partial recombinant protein with GST tag. ... Accession: BC015528 ... OMIM: 604495, GeneID: ...

Biology Products:

hERG-CHO K1 Recombinant Cell Line from Upstate Mouse Anti-Human CHD8 Monoclonal Antibody, Unconjugated, Clone 2C8 from Abnova Corporation Mouse Anti-Human PASK Monoclonal Antibody, Unconjugated, Clone 6D10 from Abnova Corporation Mouse Anti-NFKBIB Monoclonal Antibody, Unconjugated, Clone 2B11 from Abnova Corporation

First Pediatric Patient Treated With Aptocine(TM), a Novel Light-Activated Drug, in Neurofibromat...( BELLEVUE Wash. Aug. 12 /-...)